AF
LUCD icon

Amalgamated Financial’s Lucid Diagnostics LUCD Stock Holding History

Amalgamated Financial’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$3K Buy
+756
New +$2.76K ﹤0.01% 2980

Other funds holding LUCD

LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Amalgamated Financial's LUCD Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Lucid Diagnostics (LUCD) in Q1 2022: 756 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #2980 among its holdings.

32 funds tracked by Wall St. Rank hold LUCD as of Q1 2022.

  • Amalgamated Financial held 756 shares of Lucid Diagnostics worth $3K as of Q1 2022.
  • Lucid Diagnostics was a new Amalgamated Financial position in Q1 2022.
  • Lucid Diagnostics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2980 holding.
  • 32 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.